260 related articles for article (PubMed ID: 23475513)
1. Absence of immunostaining for growth hormone in a subset of patients with acromegaly.
Schroeder JL; Spiotta AM; Fleseriu M; Prayson RA; Hamrahian AH; Weil RJ
Pituitary; 2014 Apr; 17(2):103-8. PubMed ID: 23475513
[TBL] [Abstract][Full Text] [Related]
2. Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.
Cheng S; Al-Agha R; Araujo PB; Serri O; L Asa S; Ezzat S
PLoS One; 2013; 8(9):e73543. PubMed ID: 24039977
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Factors of Acromegalic Patients with Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Surgery.
Taweesomboonyat C; Oearsakul T
World Neurosurg; 2021 Feb; 146():e1360-e1366. PubMed ID: 33309643
[TBL] [Abstract][Full Text] [Related]
4. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
5. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
Schwyzer L; Starke RM; Jane JA; Oldfield EH
J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
[TBL] [Abstract][Full Text] [Related]
7. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
[TBL] [Abstract][Full Text] [Related]
8. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center.
Gheorghiu ML; Găloiu S; Vintilă M; Purice M; Hortopan D; Dumitraşcu A; Coculescu M; Poiană C
Hormones (Athens); 2016 Apr; 15(2):224-234. PubMed ID: 27376425
[TBL] [Abstract][Full Text] [Related]
10. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor.
Kola B; Korbonits M; Diaz-Cano S; Kaltsas G; Morris DG; Jordan S; Metherell L; Powell M; Czirják S; Arnaldi G; Bustin S; Boscaro M; Mantero F; Grossman AB
Clin Endocrinol (Oxf); 2003 Sep; 59(3):328-38. PubMed ID: 12919156
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary Register.
Arnardóttir S; Järås J; Burman P; Berinder K; Dahlqvist P; Erfurth EM; Höybye C; Larsson K; Ragnarsson O; Ekman B; Edén Engström B
Eur J Endocrinol; 2022 Feb; 186(3):329-339. PubMed ID: 35007208
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.
Petersenn S; Farrall AJ; De Block C; Melmed S; Schopohl J; Caron P; Cuneo R; Kleinberg D; Colao A; Ruffin M; Hermosillo Reséndiz K; Hughes G; Hu K; Barkan A
Pituitary; 2014 Apr; 17(2):132-40. PubMed ID: 23529827
[TBL] [Abstract][Full Text] [Related]
13. The pathogenesis of acromegaly. Clinical and immunocytochemical analysis in 75 patients.
Laws ER; Scheithauer BW; Carpenter S; Randall RV; Abboud CF
J Neurosurg; 1985 Jul; 63(1):35-8. PubMed ID: 4009272
[TBL] [Abstract][Full Text] [Related]
14. Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria.
Kreutzer J; Vance ML; Lopes MB; Laws ER
J Clin Endocrinol Metab; 2001 Sep; 86(9):4072-7. PubMed ID: 11549628
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients with surgical intractable acromegaly after linear accelerator radiosurgery.
Yan JL; Chang CN; Chuang CC; Hsu PW; Lin JD; Wei KC; Lee ST; Tseng JK; Pai PC; Chen YL
J Formos Med Assoc; 2013 Jul; 112(7):416-20. PubMed ID: 23927981
[TBL] [Abstract][Full Text] [Related]
16. Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.
Shimon I; Nass D; Hadani M
Pituitary; 2000 May; 2(4):289-94. PubMed ID: 11081151
[TBL] [Abstract][Full Text] [Related]
17. Octreotide treatment results in the inhibition of GH gene expression in the adenoma of the patients with acromegaly.
Tsukamoto N; Nagaya T; Kuwayama A; Takano K; Shizume K; Sugita K; Seo H
Endocr J; 1994 Aug; 41(4):437-44. PubMed ID: 8528360
[TBL] [Abstract][Full Text] [Related]
18. Transsphenoidal surgery for growth hormone-secreting pituitary adenomas in 130 patients.
Shirvani M; Motiei-Langroudi R
World Neurosurg; 2014 Jan; 81(1):125-30. PubMed ID: 23313263
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Yamaguchi H; Shimatsu A; Okayama A; Sato T
Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
[TBL] [Abstract][Full Text] [Related]
20. Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly.
Scaroni C; Albiger N; Daniele A; Dassie F; Romualdi C; Vazza G; Regazzo D; Ferraù F; Barresi V; Maffeis V; Gardiman MP; Cannavò S; Maffei P; Ceccato F; Losa M; Occhi G
J Clin Endocrinol Metab; 2019 Mar; 104(3):856-862. PubMed ID: 30285115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
